MetLife Investment Management’s Avalyn Pharma AVLN Stock Holding History

MetLife Investment Management’s Portfolio AVLN Stock Details AVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$339K	Buy	+10,308	New	+$297K	﹤0.01%	2133

Other funds holding AVLN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

MetLife Investment Management's AVLN Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Avalyn Pharma (AVLN) in Q2 2026: 10,308 shares worth $339K. The stake represents ﹤0.01% of the portfolio and ranks #2133 among its holdings.

93 funds tracked by Wall St. Rank hold AVLN as of Q2 2026.

MetLife Investment Management held 10,308 shares of Avalyn Pharma worth $339K as of Q2 2026.
Avalyn Pharma was a new MetLife Investment Management position in Q2 2026.
Avalyn Pharma made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2133 holding.
93 funds tracked by Wall St. Rank held Avalyn Pharma as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.